NY-ESO-1 expression and disease stage. There was a significant association between a more advanced disease stage at the time of diagnosis and NY-ESO-1 expression [stage I (3.45%), stage II (9.52%) and stage III (45.45%); P = 0.0014, Cochran-Armitage trend test].